Metrics as of 10/15/2026, 11:08 AM (Berlin time), refresh in progress.
Owlet, Inc.
Owlet, Inc. is a U.S.-based company that provides a digital platform specifically designed to support parents. Its primary objective is to equip families with immediate, valuable data and insights concerning their children. The company's product portfolio includes the Smart Sock, an advanced infant monitor that…
1D
-4.8%
1W
-6.8%
1M
-6.6%
6M
-22.1%
YTD
-72.8%
1Y
-50.6%
2Y
+0.5%
5Y
-91.8%
10Y
–
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~47% stronger price swings than usual
PRICE TARGET LOW
US$20.00
CONSENSUS
US$108.00
MEDIAN
US$108.00
PRICE TARGET HIGH
US$196.00
0
STRONG BUY
4
BUY
2
HOLD
0
SELL
0
STRONG SELL
6
TOTAL · Buy
As of: 22/06/2026
P/E
-10.26
P/B
3.23
EV/EBITDA
-18.62
RETURN ON EQUITY
-1.5%
NET MARGIN
-1.8%
DEBT/EQUITY
0.09
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
54.1%
FLOAT SHARES
15,797,193
AVG. DAILY VOLUME (30D)
170,377
Workman Kurt
BURKE ZANE M
Stoll Marc F
Stoll Marc F
BURKE ZANE M
Owlet, Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Kurt Workman, the company employs around 111 people.
The IPO was on 05/11/2020; the stock trades on NYSE under the ticker OWLT.
6 analysts rate the stock, the consensus is Buy (as of 22/06/2026).
The average price target is US$108.00, ranging from US$20.00 to US$196.00, with a median of US$108.00.
This is an external assessment, not a statement by Market Jury.
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 47% stronger than usual.
No, Owlet currently does not pay a dividend.
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
Clicking "Analyze stock" lets five strategies assess Owlet against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.